- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | EXTRAWELL PHAR (00858): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 AUGUST 2025 | 2 | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 15.08. | EXTRAWELL PHAR (00858): ISSUE OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025, CIRCULAR DATED 29 ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR USE BY SHAREHOLDERS AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 22 AUGUST 2025 AT 11:00 A.M. | - | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL ... | 1 | HKEx | ||
| 28.07. | EXTRAWELL PHAR (00858): ANNUAL REPORT 2025 | 3 | HKEx | ||
| 03.07. | EXTRAWELL PHAR (00858): TERMS OF REFERENCE OF NOMINATION COMMITTEE | 1 | HKEx | ||
| 30.06. | EXTRAWELL PHAR (00858): ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2025 | 1 | HKEx | ||
| 23.06. | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 17.06. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | - | HKEx | ||
| 28.03. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 28 MARCH 2025 | - | HKEx | ||
| 13.03. | EXTRAWELL PHAR (00858): SUPPLEMENTAL ANNOUNCEMENT, PROPOSED APPOINTMENT OF AUDITOR, NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON FRIDAY, 28 MARCH 2025 AT 11:00 A.M. | - | HKEx | ||
| 12.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR AND NOTICE OF SPECIAL GENERAL MEETING | - | HKEx | ||
| 07.03. | EXTRAWELL PHAR (00858): PROPOSED APPOINTMENT OF AUDITOR | 1 | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 36,180 | -0,19 % | XFRA ISI: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILIONIS PHARMACEUT.... ► Artikel lesen | |
| CSPC PHARMA | 1,152 | -1,33 % | HSI Down 304 pts; HSTI Down 42 pts; CSPC PHARMA Down over 4%; ZIJIN MINING, NAGACORP, HUABAO INTL, CHINAGOLDINTL, CTIHK Hit New Highs; Market Turnover Rises | ||
| SELLAS LIFE SCIENCES | 1,550 | -1,15 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification | - Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 21,950 | -0,72 % | Acadia Names Konstantina Katcheves as Senior VP, Chief Business & Strategy Officer | ||
| MADRIGAL PHARMACEUTICALS | 364,90 | -0,05 % | Madrigal Pharmaceuticals: Ein möglicher Favorit unter den Biotech-Aktien? | Die Aktie von Madrigal Pharmaceuticals zeigt seit Wochen eine deutliche Aufwärtsbewegung. Könnte das Biotech-Unternehmen vom neuen Branchentrend profitieren Den vollständigen Artikel lesen ... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,270 | +0,82 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,058 | +0,87 % | Enzon Pharmaceuticals, Inc: Enzon and Viskase Enter into Merger Agreement | CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) ("Enzon" or the "Company") and Viskase Companies, Inc. (OTC Pink Limited: VKSC) ("Viskase")... ► Artikel lesen | |
| OPUS GENETICS | 1,054 | +1,74 % | Opus Genetics schließt Privatplatzierung über 3,5 Millionen US-Dollar ab | ||
| SAVARA | 2,680 | -6,29 % | Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,019 | -100,00 % | NSE - Viracta Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| GALECTIN THERAPEUTICS | 3,500 | +2,34 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 5,610 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) | August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone | TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 0,878 | 0,00 % | NovaBay declares $0.80 dividend |
Das Unternehmen EXTRAWELL PHARMACEUTICAL HOLDINGS LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.